Due to promising current data on TCZ, anakinra is being investigated in a phase II/III open label, controlled, parallel, three arm study versus Emapalumab or standard of care [11]. Emapalumab is a monoclonal antibody against IFN-γ, which is currently being used in the treatment of hemophagocytic lymphohistiocytosis, a life-threatening disease caused by excessive immune activation [12]. Here, IFNG is linked to hemophagocytic syndrome.